Study guide
1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines
Key Takeaways Explain This Topic AI
Cervical oncogenesis is driven primarily by persistent infection with high-risk HPV (hrHPV) genotypes 16 and 18, which encode viral oncoproteins E6 and E7 that degrade p53 and inactivate retinoblastoma protein (pRb), respectively.
Routine cervical cancer screening begins at age 21 with cytology every 3 years; co-testing is not used before 30 because transient HPV infection is common, although ACS and ACOG accept primary hrHPV testing every 5 years from age 25.
For women aged 30 to 65, the final USPSTF (2018) statement accepts primary hrHPV every 5 years, co-testing every 5 years, or cytology every 3 years; ACS (2020) and the 2024 USPSTF draft prefer primary hrHPV, and the draft accepts patient-collected samples.
Screening may cease at age 65 if the patient has adequate negative prior screening (3 consecutive negative cytology or 2 negative co-tests within 10 years, with the most recent within 5 years) and no history of CIN 2+ within the past 25 years.
The 2019 ASCCP Consensus Guidelines dictate management based on personalized risk thresholds for immediate CIN 3+: ≥60% warrants expedited treatment, 25%–59% allows expedited treatment or colposcopy, 4.0%–24% mandates colposcopy, and <4.0% indicates clinical surveillance.
Last updated: October 2026
Cervical Anatomy & Oncogenic HPV Pathophysiology
The cervix consists of an outer ectocervix (stratified squamous epithelium) and an internal endocervical canal (simple columnar mucus-secreting epithelium), meeting at the squamocolumnar junction (SCJ) . Estrogen exposure and vaginal acidity induce squamous metaplasia, forming the transformation zone (TZ) . Because immature metaplastic cells are vulnerable to human papillomavirus (HPV) integration, >90% of cervical intraepithelial neoplasia (CIN) and invasive cancers originate here.
High-Risk vs. Low-Risk HPV Genotypes
HPV is a double-stranded DNA virus transmitted via mucosal contact. Over 100 strains exist:
High-Risk HPV (hrHPV): Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 . Types 16 and 18 cause ~70% of invasive cervical cancers (HPV 16 causes ~50% of squamous cell carcinomas; HPV 18 causes ~50% of cervical adenocarcinomas).
Low-Risk HPV: Types 6 and 11 are non-oncogenic, causing >90% of condylomata acuminata and benign low-grade lesions.
Molecular Oncogenesis: E6 and E7 Oncoproteins
Viral integration disrupts the viral E2 repressor, causing persistent transcription of E6 and E7 :
E6 oncoprotein: Binds tumor suppressor p53 and mediates ubiquitin-proteasomal degradation, abolishing p53-dependent DNA repair and apoptosis.
E7 oncoprotein: Binds retinoblastoma protein (pRb) , displacing E2F transcription factors and driving unregulated G1/S cell cycle progression.
Cervical Cancer Screening Guidelines
Protocols from USPSTF, ACOG, and ACS balance cancer detection against overdiagnosis:
Age Cohort USPSTF & ACOG Guidelines ACS Recommendations (2020) Clinical Rationale
< 21 Years No screening , regardless of sexual coitus initiation. No screening Up to 90% of adolescent HPV infections clear within 24 months; excisional therapy causes cervical stenosis and preterm labor.
21–29 Years Cytology alone every 3 years. No co-testing; ACOG accepts primary hrHPV every 5 years from age 25. Primary hrHPV every 5 years starting at age 25. High transient HPV prevalence causes excessive false-positive rates for primary HPV screening in women in their 20s.
30–65 Years Three acceptable options (USPSTF 2018 final): 1. Primary hrHPV alone every 5 years; 2. Co-testing (cytology + hrHPV) every 5 years; 3. Cytology alone every 3 years. The 2024 USPSTF draft favors primary hrHPV, clinician- or patient-collected. Primary hrHPV alone every 5 years (preferred). If unavailable, co-testing q5y or cytology q3y. Primary hrHPV has higher sensitivity for CIN 3+ than cytology alone, providing superior long-term reassurance after a negative test.
> 65 Years Discontinue screening if adequate negative prior screening criteria are met and no CIN 2+ history. Discontinue screening if criteria met. Incidence of new oncogenic infections declines; postmenopausal atrophy increases false-positive cytology.
Note
The FDA approved self-collected vaginal samples for HPV testing in a health care setting in 2024 and an at-home collection device in 2025. Self-collection suits primary hrHPV screening (not cytology), and a positive result still needs clinician follow-up.
Screening Cessation Criteria at Age 65
Discontinue screening at age 65 only with documented adequate negative prior screening :
Three consecutive negative cytology results within the past 10 years, OR
Two consecutive negative co-tests or negative primary hrHPV tests within 10 years, with the most recent test within 5 years .
No CIN 2+ history: Patients with treated CIN 2, CIN 3, or AIS must continue routine screening for at least 25 years post-treatment, even beyond age 65.
Special Populations
Immunocompromised Patients (HIV, organ transplant, systemic lupus): Screen at HIV diagnosis or sexual onset (starting by age 21). In patients with HIV, obtain cytology at diagnosis and then annually; after 3 consecutive normal annual results, screen every 3 years for life. Co-testing is permitted at age 30+. Screening continues beyond age 65.
In Utero DES Exposure: Annual cytology combined with visual and digital inspection of the entire vaginal vault to detect clear cell adenocarcinoma.
Post-Hysterectomy with Cervix Removed (for Benign Disease): Discontinue screening; vaginal cuff cytology is not indicated. If the cervix was retained ( supracervical hysterectomy ), continue routine screening. If hysterectomy was performed for CIN 2+, continue vaginal cuff screening for 25 years.
2019 ASCCP Risk-Based Management Guidelines
The 2019 ASCCP Guidelines use personalized risk estimation . Management compares a patient's immediate risk and 5-year risk of CIN 3+ against clinical action thresholds ( "Equal Management for Equal Risk" ):
Immediate CIN 3+ Risk ASCCP Management Directive Representative Clinical Scenarios
≥ 60% Expedited treatment (LEEP/conization) preferred ; colposcopy acceptable. HPV 16-positive with HSIL cytology in patients aged ≥25 with incomplete past screening.
25% to 59% Expedited treatment or colposcopy acceptable. HSIL cytology with any hrHPV positive, or HPV 16+ with ASC-H cytology.
4.0% to 24% Diagnostic colposcopy recommended. ASC-US with hrHPV positive (risk ~4.5%); LSIL with hrHPV positive or unknown; Persistent hrHPV positive with normal cytology
< 4.0% Surveillance recommended (Colposcopy deferred):
5-yr risk ≥ 0.55% • 1-year repeat surveillance: Co-test in 12 months. hrHPV positive with normal cytology, negative HPV 16/18 genotyping.
5-yr risk 0.15%–0.54% • 3-year repeat surveillance: Repeat screening in 3 years. ASC-US with negative hrHPV, or normal cytology with negative prior screening.
5-yr risk < 0.15% • 5-year routine return: Standard population screening. Negative primary hrHPV or negative co-test with negative history.
Important
Expedited treatment without preliminary biopsy is contraindicated in pregnancy, patients planning future childbearing where cervical incompetence is a concern, and patients under age 25.
Management of Specific Cytologic Abnormalities
ASC-US: Reflex hrHPV testing is preferred. If hrHPV is positive (immediate risk ~4.5%), perform diagnostic colposcopy . If hrHPV is negative, resume screening in 3 years. In patients aged 21–24, repeat cytology alone at 12 months.
LSIL: In women aged 25+, colposcopy is indicated if hrHPV is positive or unknown. If hrHPV is negative, repeat co-testing in 1 year. In women aged 21–24, repeat cytology at 12 months is preferred.
ASC-H: Immediate colposcopy is mandatory in all age groups regardless of HPV status (CIN 2+ risk 20%–50%).
HSIL: Immediate CIN 3+ risk >25%. In nonpregnant patients aged ≥25, expedited treatment (LEEP) or colposcopy is acceptable; expedited treatment is preferred if HPV 16 is positive.
Atypical Glandular Cells (AGC): High risk for invasive adenocarcinoma of cervix, endometrium, fallopian tubes, or ovaries. Workup requires diagnostic colposcopy with endocervical curettage (ECC) . In addition, endometrial biopsy (EMB) is mandatory in:
- All patients aged 35 and older with AGC
- Patients under 35 with endometrial cancer risk factors (abnormal bleeding, obesity, PCOS, nulliparity)
Atypical Endometrial Cells: Primary workup is diagnostic endometrial biopsy and endocervical curettage , alongside colposcopy.